Aquestive Therapeutics
Pharmaceuticals, 30 Technology Dr, Warren, New Jersey, 07059, United States, 51-200 Employees
Phone Number: +19*********
Who is AQUESTIVE THERAPEUTICS
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients problems with current standards of care and provide transformative products t...
Read More
-
Headquarters: 30 Technology Dr, Warren, New Jersey, 07059, United States
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
-
CEO:
Daniel Barber
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 621111 |
Show More
Does something look wrong? Fix it. | View contact records from AQUESTIVE THERAPEUTICS
Aquestive Therapeutics Org Chart and Mapping
Similar Companies to Aquestive Therapeutics
Biohaven
-
201-500
-
$ 250 Million to 500 Million
Regeneron
-
10001+
-
$ 1 Billion and Over
Sage Therapeutics
-
501-1000
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Aquestive Therapeutics
Answer: Aquestive Therapeutics's headquarters are located at 30 Technology Dr, Warren, New Jersey, 07059, United States
Answer: Aquestive Therapeutics's phone number is +19*********
Answer: Aquestive Therapeutics's official website is https://aquestive.com
Answer: Aquestive Therapeutics's revenue is $50 Million to $100 Million
Answer: Aquestive Therapeutics's SIC: 2834
Answer: Aquestive Therapeutics's NAICS: 621111
Answer: Aquestive Therapeutics has 51-200 employees
Answer: Aquestive Therapeutics is in Pharmaceuticals
Answer: Aquestive Therapeutics top competitors include: Biohaven , Regeneron , Sage Therapeutics
Answer: Aquestive Therapeutics contact info: Phone number: +19********* Website: https://aquestive.com
Answer: Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month